NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ATANIS Biotech AG

ATANIS Biotech AG

Private
BernHealthcare & Life Scienceshttps://www.atanis-biotech.com/

Last Round

Grant

Feb 20, 2025

Total Funding Raised

$2M

Company Overview

ATANIS Biotech AG is a biotechnology company that develops a novel, cell-based allergy diagnostic assay called FAST-PASE® to safely and accurately assess allergic reactions in a test tube.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

allergy diagnosticsmast cell activationex vivo assayoral food challengeOFCfood allergy testingbiomarker developmentpreclinical researchallergenicity assessmentcontract researchCROdrug discoverylab-based testingallergy lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ATANIS Biotech AG Comps

Public and private peers based on sector, stage, and business model.

ATANIS Biotech AG comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ATANIS Biotech AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 20, 2025
Early FundingOct 22, 2024
Early FundingMar 28, 2023

Key People

Founding team and executive leadership

Jean-Pierre Kinet

Chief Executive Officer, Founder and Chairman

Founding Team

Erwan Eriau

Chief Operating Officer

Executive Team

ATANIS Biotech AG Investors

Notable investors and investment history

ATANIS Biotech AG investors
InvestorRounds
AllerFundEarly Funding
Spectrum Moonshot FundEarly Funding
iXLife CapitalEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Grew 21% QoQ, from 19 to 23 employees.

ATANIS Biotech AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ATANIS Biotech AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ATANIS Biotech AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersBern
Employee Range27
Year Founded2021
Last FundingFeb 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.